CTX340™ and CTX450™ utilize LNP-based delivery of CRISPR/Cas9 gene editing cargo to the liver, targeting angiotensinogen (AGT) for refractory hypertension and 5’-aminolevulinate synthase 1 ...

About IMNN-001 Immunotherapy Designed using IMUNON's proprietary TheraPlas® platform technology, IMNN-001 is an IL-12 DNA plasmid vector encased in a nanoparticle delivery system that enables ...

IMNN-001, based on the company’s proprietary TheraPlas® technology platform, is an interleukin-12 (IL-12) DNA plasmid vector encased in a nanoparticle delivery ... 001 in an oral presentation ...

“We are particularly excited to be presenting, in the prestigious Presidential Symposium, our potent combination of epigenetic regulation and capsid delivery capabilities as an anticipated one ...

BOSTON--(BUSINESS WIRE)--nChroma Bio (“nChroma”), a genetic medicines company advancing programmable in vivo delivery to overcome ... one for oral presentation and two for poster presentations ...

Candel Therapeutics announced an oral presentation of CAN-2409 data at the ASCO Annual Meeting, focusing on prostate cancer treatment. Candel Therapeutics, Inc. announced the acceptance of an ...

Numerous approaches have been or are being evaluated for optimal oral delivery, including live vectors, various particulate formulations, mucosal adjuvants and transgenic plants. Recent progress ...

Merck & Co.'s peptides could be undergoing a transformation into oral tablets thanks to a $493 million licensing deal the company inked with Austria-based drug delivery technology maker Cyprumed.

Results are being highlighted in an oral presentation at the 2025 American ... an IL-12 DNA plasmid vector encased in a nanoparticle delivery system that enables cell transfection followed by ...